Baxter Extraneal Phase IV Mortality Study Recommended By FDA Committee
Executive Summary
Baxter's dialysis agent Extraneal should be studied in Phase IV trials measuring hypertension and mortality, FDA's Cardiovascular & Renal Drugs Advisory Committee recommended Aug. 9.